Dendreon Asks FDA to OK Prostate Drug
13th Nov 2006, 21:51 GMT
Cancer-treatment developer Dendreon said it submitted the final portion of a biologics license application to the FDA.
Dendreon Asks FDA to OK Prostate Drug related news:
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- Dendreon Completes Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer — Government/ Industry Regulation News from StratCenter.com
- Dendreon seeks OK for Provenge — United Press International - Health Business
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- Aeterna prostate cancer drug shows promise — Pharmaceutical Business Review Latest News
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
- FDA Seeks Boost in Drug Company Fees — Financial News News from StratCenter.com
Latest news from Government/ Industry Regulation News from StratCenter.com:
- PLC Systems to Show RenalGuard at Medica 2006
- National Public Health Summit Targets Cervical Cancer Elimination
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product
- Portrait PSR3 by Rhytec named in TIME Magazine's 2006 Skin Technology Story
- Pharsight Invited to Present on Model-Based Drug Development rd Annual Australian Health and Medical Research Congress
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ
- Sector Election Boosts Stem Cells
- AUDIO From Medialink and AARP: Voters' Call for Change Signals New Directions for Health Care
- Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance